These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17719285)

  • 21. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions.
    Li JJ; Qin XW; Yang XC; Li ZC; Zeng HS; Xu B; Gao Z; Wu YJ; Zhang X; Zhang CY
    Clin Chim Acta; 2008 Oct; 396(1-2):38-42. PubMed ID: 18634770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial.
    Moreno R; García E; Teles R; Rumoroso JR; Cyrne Carvalho H; Goicolea FJ; Moreu J; Mauri J; Sabaté M; Mainar V; Patricio L; Valdés M; Fernández Vázquez F; Sánchez-Recalde A; Galeote G; Jimenez-Valero S; Almeida M; Lopez de Sa E; Calvo L; Plaza I; Lopez-Sendón JL; Martín JL;
    Circ Cardiovasc Interv; 2013 Feb; 6(1):21-8. PubMed ID: 23403384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II).
    Teeuwen K; Van den Branden BJ; Rahel BM; Laarman GJ; Tijssen JG; Kelder JC; Slagboom T; Ten Berg JM; Suttorp MJ
    EuroIntervention; 2013 Jun; 9(2):212-9. PubMed ID: 23392450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Alfonso F; Pérez-Vizcayno MJ; Hernández R; Bethencourt A; Martí V; López-Mínguez JR; Angel J; Iñiguez A; Morís C; Cequier A; Sabaté M; Escaned J; Jiménez-Quevedo P; Bañuelos C; Suárez A; Macaya C;
    J Am Coll Cardiol; 2008 Nov; 52(20):1621-7. PubMed ID: 18992651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry.
    Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):173-7. PubMed ID: 16144017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial.
    Park DW; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Seong IW; Lee JH; Tahk SJ; Jeong MH; Jang Y; Cheong SS; Yang JY; Lim DS; Seung KB; Chae JK; Hur SH; Lee SG; Yoon J; Lee NH; Choi YJ; Kim HS; Kim KS; Kim HS; Hong TJ; Park HS; Park SJ
    J Am Coll Cardiol; 2010 Oct; 56(15):1187-95. PubMed ID: 20883925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.
    Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF
    Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design.
    Pfisterer M; Bertel O; Bonetti PO; Brunner-La Rocca HP; Eberli FR; Erne P; Galatius S; Hornig B; Kiowski W; Pachinger O; Pedrazzini G; Rickli H; De Servi S; Kaiser C;
    Am Heart J; 2008 Apr; 155(4):609-14. PubMed ID: 18371466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
    Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
    J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study.
    Toutouzas K; Patsa C; Tsiamis E; Tsioufis C; Spanos A; Stefanadi E; Tentolouris C; Stefanadis C
    J Interv Cardiol; 2008 Oct; 21(5):388-94. PubMed ID: 18705639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
    Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
    Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
    Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
    Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
    Teeuwen K; Van den Branden BJ; Koolen JJ; van der Schaaf RJ; Henriques JP; Tijssen JG; Kelder JC; Vermeersch PH; Rensing BJ; Suttorp MJ
    EuroIntervention; 2015 Mar; 10(11):1272-5. PubMed ID: 25136884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III.
    Mehta RH; Leon MB; Sketch MH;
    Am J Cardiol; 2007 Oct; 100(8B):62M-70M. PubMed ID: 17950834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.